What changed in 2026, by region

What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked.

Documenting an access outcome, dated, because everything in this category expires.

As of April 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.

Written quickly, so the reasoning may be tighter than the wording.

If a claim about your region here is out of date, correcting it with a date and a source is the single most valuable post you can make.

One of those cases where knowing the mechanism does not help the decision.

Post #2 put the caveat in the right place and I want to underline it.

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.

If anyone has run this properly I would rather read that than my own guess.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

Not a strong opinion, just a consistent one.

Taking post #4 at face value and following it one step further.

Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.

Picking up post #8: that is the part I would want checked first.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

The literature is thinner on this than the confidence in the thread implies.

On post #6 — agreed on the reasoning, with one qualification.

A first-hand dated account for a region with thin coverage is worth more here than any summary, and the regions with thin coverage are most of them.

That reframing is the whole thing. The facts I already had.

Taking post #9 at face value and following it one step further.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

This is where my knowledge stops and I would rather mark the edge than blur it.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.

I have seen it go both ways, which is why I hedge.